Early adoption of triamcinolone acetonide suprachoroidal injection for uveitic macular edema: a physician survey.
Macular edema
Retina
Suprachoroidal injection
Survey
Treatment
Uveitis
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
received:
02
02
2024
accepted:
07
10
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
To obtain physicians' "real-world" perspectives on early experiences with triamcinolone acetonide suprachoroidal injection (SCS-TA) for treatment of patients with uveitic macular edema (UME). Twelve retina/uveitis specialists in the United States were surveyed about SCS-TA injection procedure and patient outcomes. Survey participants administered ≥ 291 SCS-TA injections to 243 patients with UME with various disease characteristics (etiologies, chronicity, and anatomical subtypes). Commonly reported reasons for SCS-TA adoption included potential for lowering the risk of steroid-associated intraocular pressure elevations versus intravitreal injections or implants (100%), potential for longer duration of action versus intravitreal steroid injections or implants (92%), and desire to use a new delivery modality (83%). Nearly all participants (92%) found injection procedure relatively easy post-training, with most (75%) procedurally comfortable after completing 2-5 injections. 58% of participants indicated that their patients gained 2-3 lines of vision by first follow-up visit, and 92% reported having patients who experienced 100-150 μm or greater reduction in central subfield thickness. Overall, 92% of participants were satisfied with SCS-TA treatment outcomes. Findings from this survey of early adopters of SCS-TA indicate that the suprachoroidal injection technique was easy to learn and resulted in favorable patient outcomes consistent with clinical trial data.
Identifiants
pubmed: 39444009
doi: 10.1186/s13104-024-06969-4
pii: 10.1186/s13104-024-06969-4
doi:
Substances chimiques
Triamcinolone Acetonide
F446C597KA
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
317Informations de copyright
© 2024. The Author(s).
Références
Massa H, Pipis SY, Adewoyin T, Vergados A, Patra S, Panos GD. Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol. 2019;13:1761–77.
doi: 10.2147/OPTH.S180580
pubmed: 31571815
pmcid: 6750710
Cunningham ETE, Zierhut M. Vision loss in uveitis. Ocul Immunol Inflamm. 2021;29(6):1037–9.
doi: 10.1080/09273948.2021.2017152
Lardenoye CWTA, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113(8):1446–9.
doi: 10.1016/j.ophtha.2006.03.027
pubmed: 16877081
Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos PG. Update in treatment of uveitic macular edema. Drug Des Devel Ther. 2019;13:667–80.
doi: 10.2147/DDDT.S166092
pubmed: 30858697
pmcid: 6387597
Habot-Wilner Z, Noronha G, Wykoff CC. Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. Acta Ophthalmol. 2019;97(5):460–72.
doi: 10.1111/aos.14042
pubmed: 30702218
Wan C-R, Muya L, Kansara V, Ciulla TA. Suprachoroidal delivery of small molecules, nanoparticles, gene and cell therapies for ocular diseases. Pharmaceutics. 2021;13(2):288.
doi: 10.3390/pharmaceutics13020288
pubmed: 33671815
pmcid: 7926337
XIPERE (triamcinolone. Acetonide injectable suspension), for suprachoroidal use [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc.; 2022.
Wan C-R, Kapik B, Wykoff CC, et al. Clinical characterization of suprachoroidal injection procedure utilizing a microinjector across three retinal disorders. Transl Vis Sci Technol. 2020;9(11):27.
doi: 10.1167/tvst.9.11.27
pubmed: 33150052
pmcid: 7585395
Chiang B, Jung JH, Prausnitz MR. The suprachoroidal space as a route of administration to the posterior segment of the eye. Adv Drug Deliv Rev. 2018;126:58–66.
doi: 10.1016/j.addr.2018.03.001
pubmed: 29545195
pmcid: 5995649
Yeh S, Khurana RN, Shah M, et al. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial. Ophthalmology. 2020;127(7):948–55.
doi: 10.1016/j.ophtha.2020.01.006
pubmed: 32173113
Henry CR, Shah M, Barakat MR, et al. Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA). Br J Ophthalmol. 2022;106(6):802–6.
doi: 10.1136/bjophthalmol-2020-318019
pubmed: 33547034
Khurana RN, Merrill P, Yeh S, et al. Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA). Br J Ophthalmol. 2022;106(8):1139–44.
pubmed: 33712478
Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol. 2011;151(2):329–32.
doi: 10.1016/j.ajo.2010.08.039
pubmed: 21168821
Liechty JJ, Wilkinson MJ, Bowie EM. Assessment of intravitreal injection training among U.S.-based ophthalmology residents. J Acad Ophthalmol. 2019;11(01):e43–9.
doi: 10.1055/s-0039-1688912
Chaturvedi R, Wannamaker KW, Riviere PJ, Khanani AM, Wykoff CC, Chao DL. Real-world trends in intravitreal injection practices among American retina specialists. Ophthalmol Retina. 2019;3(8):656–62.
doi: 10.1016/j.oret.2019.03.023
pubmed: 31133544
pmcid: 6684447
Ali BM, Azmeh AM, Alhalabi NM. Suprachoroidal triamcinolone acetonide for the treatment of macular edema associated with retinal vein occlusion: a pilot study. BMC Ophthalmol. 2023;23(1):60.
doi: 10.1186/s12886-023-02808-5
pubmed: 36765332
pmcid: 9921687
Rujkorakarn P, Zhou A, Babiker F, Chang PY. Suprachoroidal triamcinolone injection in posterior scleritis: a case report [published online ahead of print July 14, 2023]. Ocul Immunol Inflamm 2023:1–4.